# (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

> **NCT02132403** · PHASE1 · TERMINATED · sponsor: **University of Illinois at Chicago** · enrollment: 3 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** BTH1704
- **DRUG:** IMPRIME PGG
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02132403
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Drug Recall
- **Last updated:** 2015-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132403, "(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02132403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*